SCHEMBL9932270

SCHEMBL9932270

Nc1ccc(F)c(NC(=O)Nc2ncnc3[nH]c(C(F)(F)F)nc23)c1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 6/20 0.38
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PARP1 P09874 1/20 0.33
FLT3 P36888 2/20 0.32
KDR P35968 7/20 0.32
EGFR P00533 2/20 0.32
FLT1 P17948 2/20 0.32
FLT4 P35916 2/20 0.32
GSK3A P49840 2/20 0.32
GSK3B P49841 2/20 0.32
TRPV1 Q8NER1 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
NTRK1 P04629 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9932260 0.88 PARP1 (0.41) BRAFPARP1KDM4EHPGD
SCHEMBL9932437 0.85 BRAF (0.39) BRAFFLT3KDREGFRFLT1
SCHEMBL9971077 0.80 BRAF (0.65) BRAF
SCHEMBL9932549 0.79 BRAF (0.41) BRAFKMT2AKDREGFRFLT1
SCHEMBL9932406 0.78 BRAF (0.42) BRAFKMT2AFLT3
SCHEMBL9933089 0.76 BRAF (0.40) BRAFKMT2AEGFR
SCHEMBL9931500 0.74 BRAF (0.47) BRAFEGFR
SCHEMBL9932327 0.73 BRAF (0.63) BRAFFLT3KDR
SCHEMBL9932914 0.73 BRAF (0.49) BRAFFLT3KDREGFRFLT1
SCHEMBL9932430 0.72 BRAF (0.38) BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157453-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157453-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF BRAF 1/4885MEN1 1047/4885POLB 2185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.